1-(2-氟氟苯基)-1,4-二氢-5 H-四唑-5-硫酮( HL 1 )、1-(2-甲基苯基)反应合成新的配合物( I )-( IV ) -1,4-dihydro-5 H -tetrazole-5-thione ( HL 2 ) 和 1-(2-chlorochlorophenyl)-1,4-dihydro-5 H -tetrazole-5-thione ( HL 3 ) 与氯化镉。通过X射线衍射分析,确定了配合物( I )、( II )、( III )和( IV )的分子和晶体结构。(CIF 文件 CCDC № 2,003,797(一),1,993,454(二))、2,151,359 ( III )、2,098,997 ( IV))。讨论了所有三镉金属-有机配合物的赫希菲尔德表面分析、前沿轨道分析、原子电荷、静电势、非线性光学性质和自然键分析。分子对接研究用于研究化合物与 DNA 分子的结合和相互作用,预测化合物
Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
申请人:——
公开号:US20030229120A1
公开(公告)日:2003-12-11
Novel ligands for the HisB10 Zn
2+
sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.
[EN] PHAMACEUTICAL PREPARATIONS COMPRISING INSULIN<br/>[FR] PREPARATIONS PHARMACEUTIQUES CONTENANT DE L'INSULINE
申请人:NOVO NORDISK AS
公开号:WO2006005683A1
公开(公告)日:2006-01-19
Novel preparations comprising ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer wherein the ligand is extended by protamine that are capable of prolonging the action of insulin preparations.
The present invention provides pharmaceutical compositions comprising insulin and novel ligands for the His
B10
Zn
2+
sites of the R-state insulin hexamer. The resulting preparations have improved physical and chemical stability.
[EN] PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN<br/>[FR] PREPARATIONS PHARMACEUTIQUES CONTENANT DE L'INSULINE STABILISEE D'UN POINT DE VUE ACIDE
申请人:NOVO NORDISK AS
公开号:WO2004080480A1
公开(公告)日:2004-09-23
Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer that are capable of prolonging the action of insulin preparations are disclosed.
Synthesis, Anti-Inflammatory Properties and Molecular Docking of 2-(5-Aryltetrazol-2-yl)-and 2-(1H-Tetrazol-5-ylsulphanyl)-N-Thiazol-2-ylacetamides
作者:T. I. Chaban、V. T. Foliush、V. V. Ogurtsov、V. S. Matiychuk
DOI:10.1134/s1068162021040051
日期:2021.7
5-mercaptotetrazoles 2-(5-aryltetrazol-2-yl)- and 2-(1H-tetrazol-5-ylsulfanyl)-N-thiazol-2-ylacetamides were prepared. The study of the anti-inflammatory properties of the synthesized compounds was carried out. Compounds have been identified, whose activity exceeds the reference drug ibuprofen. Molecular docking to cyclooxygenase-1 and cyclooxygenase-2 was carried out and it was shown that 2-[1-(2,5-dimet